Table 1. Prognostic surrogates in PAH.
| Exercise capacity | Functional classification 6MWD Cardiopulmonary exercise testing |
| Hemodynamics | RAP, CI, PVR, PA capacitance, MVO2, SBP |
| Imaging | Echocardiography: pericardial effusion, RV size TAPSE, Tei index CMR: RV stroke volume and mass, RVEF, RVEDV |
| Biomarkers | BNP, NT-proBNP, cardiac troponin, uric acid, DLCO |
| Risk equations | NIH registry, French National Registry, PH connection registry, REVEAL registry equation |
BNP: brain natriuretic peptide; CI: cardiac index; CMR: cardiac magnetic resonance; DLCO: diffusing capacity of lung for carbon monoxide; EDV: enddiastolic volume; MVO2: mixed venous oxygen; NIH: National Institutes of Health; NT-proBNP: N5 terminal pro-brain natriuretic peptide; PAH: pulmonary arterial hypertension; PA: pulmonary artery; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; RAP: right atrial pressure; RV: right ventricular; RVEF: right ventricular ejection fraction SBP: systolic blood pressure; 6MWD: 6-minute walk distance; TAPSE: tricuspid annular plane systolic excursion.